Interim report 2026
Filed with HKEX · Stock code 1875 · · 59 pages · English
2 Corporate information 3 Management discussion and analysis 15 Financial review 19 Report on review of condensed consolidated fi nancial statements 20 Condensed consolidated statement of profi t or loss and other comprehensive income 21 Condensed consolidated statement of fi nancial position 23 Condensed consolidated statement of changes in equity 24 Condensed consolidated statement of cash fl ow
BioDlink International Company Limited on 6ix
Earlier from BioDlink International
- BioDlink Named "Emerging CDMO of the Year" at the 2026 Asia-Pacific Biopharma Excellence Awards
- BioDlink Recognized by Client for Enabling the World's First Dual-Payload ADC to Enter Clinical Trials
- BioDlink Showcases Europe-China CMC Collaboration Amid Developmental Breakthrough
- BioDlink and Lepu Biopharma Celebrate Successful Launch of the World's First EGFR-Targeting ADC Drug, Marking a Major Milestone in Mutual Collaboration in Biologics CMC
- BioDlink Congratulates Lepu Biopharma on Securing Approval for the World's First Approved EGFR-Targeted ADC
Later from BioDlink International
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
Follow BioDlink International into a list and get an email when it puts out news.
Follow BioDlink International